Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2025-03-29 DOI:10.1002/alz.70010

Ryan T. Muir, Sophie Stukas, Jennifer G. Cooper, Andrew E. Beaudin, Cheryl R. McCreary, Myrlene Gee, Krista Nelles, Nikita Nukala, Janina Valencia, Kristopher M. Kirmess, Sandra E. Black, Michael D. Hill, Richard Camicioli, Cheryl L. Wellington, Eric E. Smith

{"title":"Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls","authors":"Ryan T. Muir, Sophie Stukas, Jennifer G. Cooper, Andrew E. Beaudin, Cheryl R. McCreary, Myrlene Gee, Krista Nelles, Nikita Nukala, Janina Valencia, Kristopher M. Kirmess, Sandra E. Black, Michael D. Hill, Richard Camicioli, Cheryl L. Wellington, Eric E. Smith","doi":"10.1002/alz.70010","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Cerebral amyloid angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ<sub>42/40</sub>, phosphorylated-tau (p-tau), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) differ in CAA and their potential to discriminate Boston Criteria 2.0 probable CAA from healthy controls.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>Plasma Aβ<sub>42/40</sub>, p-tau-181, NfL, and GFAP were quantified using single molecule array (Simoa) and Aβ<sub>42/40</sub> was also independently quantified using immunoprecipitation liquid chromatography mass-spectrometry (IPMS).</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Forty-five participants with CAA and 47 healthy controls had available plasma. Aβ<sub>42/40</sub> ratios were significantly lower in CAA than healthy controls. While p-tau-181 and NfL were elevated in CAA, GFAP was similar. A combination of Aβ<sub>42/40</sub> (Simoa), p-tau-181, and NfL resulted in an area under the curve of 0.90 (95% confidence interval: 0.80, 0.95).</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Plasma Aβ<sub>42/40</sub>, p-tau-181, and NfL differ in those with CAA and together can discriminate CAA from healthy controls.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Participants with CAA had reduced plasma Aβ<sub>42/40</sub> ratios compared to controls.</li>\n \n <li>Plasma p-tau-181 and NfL concentrations are elevated in CAA compared to controls.</li>\n \n <li>Plasma GFAP was similar in CAA and controls.</li>\n \n <li>Together, plasma Aβ<sub>42/40</sub>, p-tau-181, and NfL had excellent discriminability for CAA.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 3","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70010","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.70010","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

Cerebral amyloid angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ_42/40, phosphorylated-tau (p-tau), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) differ in CAA and their potential to discriminate Boston Criteria 2.0 probable CAA from healthy controls.

METHODS

Plasma Aβ_42/40, p-tau-181, NfL, and GFAP were quantified using single molecule array (Simoa) and Aβ_42/40 was also independently quantified using immunoprecipitation liquid chromatography mass-spectrometry (IPMS).

RESULTS

Forty-five participants with CAA and 47 healthy controls had available plasma. Aβ_42/40 ratios were significantly lower in CAA than healthy controls. While p-tau-181 and NfL were elevated in CAA, GFAP was similar. A combination of Aβ_42/40 (Simoa), p-tau-181, and NfL resulted in an area under the curve of 0.90 (95% confidence interval: 0.80, 0.95).

DISCUSSION

Plasma Aβ_42/40, p-tau-181, and NfL differ in those with CAA and together can discriminate CAA from healthy controls.

Highlights

Participants with CAA had reduced plasma Aβ_42/40 ratios compared to controls.
Plasma p-tau-181 and NfL concentrations are elevated in CAA compared to controls.
Plasma GFAP was similar in CAA and controls.
Together, plasma Aβ_42/40, p-tau-181, and NfL had excellent discriminability for CAA.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.